Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability Through Sphingosine-1-Phosphate Receptor Signaling in Endothelial Cells

Mohammad Tauseef,* Vidisha Kini,* Nebojsa Knezevic, Melissa Brannan, Ram Ramchandaran, Henrik Fyrst, Julie Saba, Stephen M. Vogel, Asrar B. Malik, Dolly Mehta

Abstract—The lipid mediator sphingosine-1-phosphate (S1P), the product of sphingosine kinase (SPHK)-induced phosphorylation of sphingosine, is known to stabilize interendothelial junctions and prevent microvessel leakiness. Here, we investigated the role of SPHK1 activation in regulating the increase in pulmonary microvessel permeability induced by challenge of mice with lipopolysaccharide or thrombin ligation of protease-activating receptor (PAR)-1. Both lipopolysaccharide and thrombin increased mouse lung microvascular permeability and resulted in a delayed activation of SPHK1 that was coupled to the onset of restoration of permeability. In contrast to wild-type mice, Spk1−/− mice showed markedly enhanced pulmonary edema formation in response to lipopolysaccharide and PAR-1 activation. Using endothelial cells challenged with thrombin concentration (50 nmol/L) that elicited a transient but reversible increase in endothelial permeability, we observed that increased SPHK1 activity and decreased intracellular S1P concentration preceded the onset of barrier recovery. Thus, we tested the hypothesis that released S1P in a paracrine manner activates its receptor S1P1 to restore the endothelial barrier. Knockdown of SPHK1 decreased basal S1P production and Rac1 activity but increased basal endothelial permeability. In SPHK1-depleted cells, PAR-1 activation failed to induce Rac1 activation but augmented RhoA activation and endothelial hyperpermeability response. Knockdown of S1P1 receptor in endothelial cells also enhanced the increase in endothelial permeability following PAR-1 activation. S1P treatment of Spk1−/− lungs or SPHK1-deficient endothelial cells restored endothelial barrier function. Our results suggest the crucial role of activation of the SPHK1→SIP→S1P1 signaling pathway in response to inflammatory mediators in endothelial cells in regulating endothelial barrier homeostasis. (Circ Res. 2008;103:1164-1172.)

Key Words: sphingosine kinase ■ lung vascular permeability ■ thrombin ■ PAR-1 ■ RhoGTPases ■ S1P1 ■ S1P

The vascular endothelium forms a semipermeable barrier separating intravascular and tissue compartments. Disruption of endothelial barrier is a crucial factor in the pathogenesis of tissue inflammation, the hallmark of inflammatory diseases such as the acute respiratory distress syndrome.1 Increased microvessel endothelial permeability leads to protein-rich alveolar edema that severely impairs oxygenation.2 Thrombin, a serine protease, generated during sepsis and intravascular coagulation, ligates the endothelial cell surface receptor protease activating receptor 1 (PAR-1) and increases endothelial permeability.1,3–6 This increase in endothelial permeability is typically followed by a recovery period of ≈2 hours, during which barrier integrity is restored.7,8 It has been surmised that PAR-1 signaling stimulates intrinsic repair mechanisms that restore barrier function.7–9 Sphingosine-1-phosphate (S1P), a lipid mediator, was shown to be 1 such factor promoting endothelial barrier function.10–13 S1P binds to S1P1 receptor in endothelial cells, leading to activation of heterotrimeric G proteins of the G1 class, and signals enhancement of endothelial barrier function through Rac1-dependent adherens junction assembly and actin cytoskeletal remodeling.10–13

Sphingosine kinases (SPHKs) catalyze the formation of S1P from sphingosine (SPH).14,15 S1P in the circulation is short-lived because of degradation by S1P phosphatase and sphingosine phosphate lyase.16 Because SPHK activity is required to replenish cellular and plasma S1P concentration,17 SPHK is a crucial checkpoint regulating S1P concentration.14,15 SPHK activity in endothelial cells largely contributes in maintaining circulating S1P concentration.16,17 SPHK is expressed as SPHK1 or SPHK2 isoforms in various cell types.15,18 In the present study, we used SPHK1 knockout mice to investigate the role of alterations in SPHK1 activity in regulating endothelial barrier function. Our results demonstrate that SPHK1-generated S1P is a crucial mechanism limiting the effects of inflammatory mediators in increasing
endothelial permeability and does so by the activation of endothelial cell S1P1 signaling pathway.

Materials and Methods

Animals, cell culture and transfection, RT-PCR, SPHK activity assay, S1P measurement, confocal imaging, endothelial permeability determination, and lung vascular permeability determination are described in the expanded Material and Methods section in the online data supplement, available at http://circres.ahajournals.org.

Results

SPHK1 Limits the Increase in Lung Vascular Permeability and Edema Formation Following PAR-1 Activation

We used Sphk1−/− mice to address the role of SPHK1 in regulating S1P generation in lung microcirculation and endothelial barrier function. RT-PCR analysis of RNA isolated from lungs of wild-type (WT) and Sphk1−/− mice showed that WT lungs expressed both SPHK1 and SPHK2 isoform, whereas only SPHK1 was absent in Sphk1−/− mice (Figure 1A, a1). Similar expression of SPHK2 was seen in RNA and lysates of lungs of WT and Sphk1−/− mice (Figure 1A, a1 and a2), indicating that loss of SPHK1 did not lead to compensatory increase in SPHK2.

We have shown that thrombin increases lung microvascular permeability through endothelial cell surface protease activating receptor (PAR)-1. Using PAR-1–specific activating peptide (TFLLRN), we determined whether PAR-1 activation alters SPHK activity in lungs. WT or Sphk1−/− mice received IV injection of either control peptide or PAR-1–activating peptide (1 mg/kg). Lungs were obtained at 45 or 90 minutes.

**Figure 1.** SPHK1 counteracts PAR-1–induced increase in lung microvascular permeability. A, SPHK expression in lungs: RT-PCR of SPHK1 RNA (a1) and protein expression (a2) in WT and Sphk1−/− lungs. a1, RNA extracted from lungs was treated with DNAase and reverse-transcribed using suitable primers as described in the expanded Materials and Methods section in the online data supplement. a2, Lung homogenates were processed for Western blotting with anti-SPHK1, anti-SPHK2, or anti-β-actin antibodies. B and C, SPHK activity and S1P concentration in lungs. Control or PAR-1 agonist peptide (1 mg/kg) were administered IV to WT and Sphk1−/− mice, and lungs were obtained at indicated times to determine SPHK enzymatic activity (B) or S1P concentrations (C). Inset in B, Representative autoradiograph showing S1P spot (arrow). Data in B and C are mean±SEM of 3 experiments. *Significant increase in activity compared to 0 time in WT lungs (P<0.05). #Significant difference from SPHK1-deficient lungs (P<0.05). D, Lung microvessel permeability (measured as Kf,c) in Sphk1−/− mice. After establishing isogravimetric condition, intravascular pressure of lungs was raised by 10 cm H2O for 20 minutes. Kf,c was determined as described in the expanded Materials and Methods section. Data are expressed as mean±SEM of 3 experiments. *Significant difference from WT under basal conditions (P<0.05). E and F, PAR-1–induced increase in lung vascular permeability is augmented in Sphk1−/− mice. PAR-1 agonist (1 mg/kg) or control peptide were injected IV into mice, and, after 30 or 90 minutes, lung vascular permeability was determined by quantifying EBAE (E) or wet/dry weight ratio (F) as described in the expanded Materials and Methods section. Data are expressed as mean±SD of 3 experiments. *Significant difference from WT control (P<0.05).
minutes and were homogenized for determination of SPHK activity using sphingosine as substrate. SPHK was constitutively active in WT lungs (Figure 1B). PAR-1 agonist peptide significantly increased SPHK activity above basal at 45 and 90 minutes (Figure 1B). However, SPHK activity under basal conditions was decreased by 5-fold in Sphk1<sup>−/−</sup> lungs, and, importantly, it did not increase following PAR-1 activation (Figure 1B). We also determined lung SIP concentrations following PAR-1 agonist peptide administration in WT and Sphk1<sup>−/−</sup> mice. Basal SIP concentration did not differ in lungs from WT and Sphk1<sup>−/−</sup> mice (Figure 1C). PAR-1 activation significantly increased SIP concentration in WT lungs but failed to induce SIP formation above basal amount in Sphk1<sup>−/−</sup> lungs (Figure 1C). These findings demonstrate that PAR-1 agonist activates SPHK1 in vivo, which generates SIP in lungs.

We next addressed the possible role of SPHK1-induced SIP synthesis in regulating lung microvascular permeability using the isolated mouse lung preparation. We determined the microvessel filtration coefficient (K<sub>f,c</sub>) in WT and Sphk1<sup>−/−</sup> lungs under basal condition and after challenge with PAR-1 agonist peptide. Basal K<sub>f,c</sub> was significantly higher in Sphk1<sup>−/−</sup> lungs than WT lungs (Figure 1D). PAR-1 activation significantly increased K<sub>f,c</sub> in WT lungs, and a greater increase was seen in Sphk1<sup>−/−</sup> lungs (Figure 1D). Other studies were made to determine the role of SPHK1 in regulating increased lung vascular permeability resulting from PAR-1 activation. In these studies, we quantified Evans blue albumin extravasation (EBAE) to determine transvascular albumin permeability and lung wet/dry weight ratio to quantify edema formation. Lung vascular albumin permeability and lung wet/dry weight ratio to quantify edema formation also significantly increased basal endothelial permeability (Figure 1E and 1F). Injection of PAR-1 peptide (IV) increased EBAE (Figure 1E) and produced edema in WT lungs (Figure 1F). Edema formation and lung vascular permeability recovered at 90 minutes in WT mice. In the absence of SPHK1, PAR-1 further augmented the increase in lung vascular permeability and edema formation (Figure 1E and 1F), indicating that SPHK1-mediated SIP generation suppresses PAR-1-induced pulmonary edema. In other studies, we determined whether loss of SPHK1 enhances the rate of edema formation following PAR-1 activation, as monitored by changes in lung wet weight in the isolated perfused lung preparation. PAR-1 agonist peptide infusion via the pulmonary artery cannula significantly increased wet weight gain in Sphk1<sup>−/−</sup> lungs compared to WT lungs (Figure 1G). Together, these results demonstrate the critical requirement of SPHK1 activity in opposing PAR-1-induced barrier dysfunction.

**Augmented Lipopolysaccharide-Induced Increase in Lung Vascular Permeability in Sphk1<sup>−/−</sup> Mice**

We addressed whether SPHK1 can also modulate increased lung vascular permeability provoked by lipopolysaccharide (LPS), known to cause neutrophil activation–mediated lung vascular leak. Sphk1<sup>−/−</sup> and WT mice received nebulized LPS by inhalation for 45 minutes as described (see expanded Materials and Methods in the online data supplement), and, after 2 or 11 hours, the mice were killed to determine SPHK activity, lung edema formation, and lung neutrophil infiltration. We observed that LPS challenge increased lung SPHK activity after 11 hours in WT mice, but not in SPHK1-deficient mice (Figure 2A). In the absence of SPHK1, LPS caused significantly greater increases in lung vascular permeability (Figure 2B) and wet/dry lung weight ratio (Figure 2C), as well as further increases in lung neutrophil sequestration (Figure 2D). The increases in lung vascular permeability and water content, as well as neutrophil sequestration, returned to normal within 11 hours in WT mice, but these responses persisted in Sphk1<sup>−/−</sup> mice.

**SPHK1 Activation Is Required for Endothelial Barrier Restoration**

To gain insight into the mechanism of SPHK1-mediated endothelial barrier repair, we studied human pulmonary arterial endothelial (HPAE) cells in which small interfering (si)RNA was used to suppress SPHK1 expression. Cells were transfected with either scrambled siRNA (control) or SPHK1 siRNA, and, after 24, 48, or 72 hours, SPHK1 Western blot analysis showed that effective knockdown of SPHK1 occurred at 72 hours posttransfection (Figure 3A, left inset). The reduction in SPHK1 expression had no effect on the expression of SPHK2 (Figure 3A, left inset). Inhibition of SPHK1 expression also markedly reduced SPHK activity compared to scrambled siRNA-transfected cells (Figure 3A, right inset). In addition, suppression of SPHK1 expression resulted in a 5-fold decrease in intracellular SIP concentration (Figure 3B).

We have shown that thrombin induces a rapid increase in endothelial permeability resulting from disruption of adherens junctions followed by recovery when junctions reanneal to restore the barrier. Because RhoA and Rac1 GTPases signal these time-dependent alterations in endothelial barrier function in response to PAR-1 agonist, we determined the role of SPHK1 knockdown and decreased SIP generation on RhoA and Rac1 activities and adherens junction assembly following thrombin challenge. In scrambled siRNA-transfected cells, thrombin increased RhoA activity and disrupted adherens junctions within 10 minutes, but thrombin did not alter Rac1 activity. However, at 2 hours after thrombin challenge, RhoA activity declined to near basal value, whereas Rac1 activity increased in association with reannealing of adherens junctions (Figure 3C through 3E). Knockdown of SPHK1 reduced basal Rac1 activity and disrupted adherens junctions in the control endothelium, leading to formation of interendothelial gaps. Thrombin induced prolonged activation of RhoA in SPHK1 knockdown cells, Rac1 activity remained suppressed, and the junctions did not reanneal (Figure 3C through 3E). SPHK1 knockdown also significantly increased basal endothelial permeability determined by transendothelial transfer of Evans blue-conjugated albumin across the endothelial monolayer (Figure 3F, left). Using transendothelial electric resistance (TER) to assess reannealing of junctions, we observed that basal TER values were significantly lower in SPHK1-siRNA transfected cells than scrambled siRNA-transfected cells (Figure 3F, right). Thrombin decreased TER in scrambled siRNA-transfected cells, which fully recovered within 2 hours.
However, after SPHK1 knockdown, thrombin also decreased TER in HPAE cells, but, in contrast to control cells, TER did not return to basal value during the 2-hour period (Figure 3F, right). To address whether SPHK1 knockdown perturbed S1P1 receptor function, we added 1 μmol/L S1P to control cells or SPHK1 siRNA-transfected cells. S1P enhanced endothelial barrier function in control cells (Figure 3F, right), whereas it restored barrier function in the SPHK1-deficient cells (Figure 3F, right).

We next addressed whether increasing SPHK1 activity would prevent thrombin-induced endothelial barrier dysfunction. Figure 3G shows SPHK activity and TER in HPAE cells infected with green fluorescent protein (GFP) (control) or SPHK1 adenovirus. Increasing SPHK1 activity by 5-fold attenuated the thrombin-induced decrease in TER and promoted endothelial barrier recovery, demonstrating the requirement of SPHK1 activation in not only maintaining normal endothelial barrier function but also promoting recovery of barrier function after endothelial junctional disruption induced by thrombin.

SPHK1-Generated S1P Restores Endothelial Barrier Function by Activating S1P1 Receptor
We performed RT-PCR using total RNA isolated from HPAE cells or mouse lungs to identify expression of S1P receptors. Both HPAE cells and mouse lungs express S1P1 receptor (Figure I in the online data supplement), which is known to signal S1P-mediated enhancement of barrier function.10–13 To address the role of S1P generated by SPHK1 in the mechanism of restoration of endothelial barrier function, we first measured SPHK activity and intracellular S1P concentration in HPAE cells following thrombin challenge. Thrombin increased SPHK activity in the same time frame as recovery of endothelial barrier function and concomitantly decreased intracellular S1P concentration (Figure 4A and 4B). We next suppressed S1P1 receptor expression using siRNA to determine whether the receptor could be activated in a paracrine manner during recovery from thrombin-induced endothelial permeability increase. As shown in Figure 4C, knockdown of S1P1 receptor prevented recovery from thrombin-induced permeability increase. As a positive control, we demonstrated

Figure 2. Enhanced LPS-induced pulmonary edema and neutrophil infiltration in Sphk1–/– mice. WT and Sphk1–/– mice were exposed to aerosolized LPS (1 mg/mL) dissolved in PBS or PBS alone for 45 minutes and at indicated times, lungs were isolated and perfused with PBS to remove blood. A, SPHK enzymatic activity in response to LPS. Lungs were homogenized, and lysates were used for in vitro determination of SPHK enzymatic activity. The inset displays a representative autoradiograph of S1P separation on thin-layer chromatography plates. Data are given as mean ± SD of 3 experiments. *Significant difference in enzyme activity compared to “no LPS” group of WT lungs (P < 0.05). #Significant difference from Sphk1–/– lungs (P < 0.05). B and C, LPS-induced transvascular albumin transport and lung edema formation. Evans blue albumin transfer to lung tissue (EBAE) (B) and lung wet/dry weight ratio (C) are plotted at 2 or 11 hours after LPS challenge. Data points represent mean ± SD of 3 experiments. *Significant difference from PBS group (ie, no LPS) (P < 0.05). #Significant difference from LPS-challenged WT group (P < 0.05). D, Quantitative analysis of increased neutrophil sequestration in Sphk1–/– mouse lungs. Lungs were fixed, sectioned, and stained with hematoxylin. The images shown at the top are representative sections, and the quantitative results for neutrophil infiltration are shown at the bottom. Note that Sphk1–/– lungs showed increased neutrophil sequestration 11 hours after LPS challenge. *Significant difference from PBS control (ie, no LPS) (P < 0.05). #Significant difference in leukocyte counts compared to WT lungs after LPS challenge (P < 0.05).

(Figure 3F, right). However, after SPHK1 knockdown, thrombin also decreased TER in HPAE cells, but, in contrast to control cells, TER did not return to basal value during the 2-hour period (Figure 3F, right). To address whether SPHK1 knockdown perturbed S1P1 receptor function, we added 1 μmol/L S1P to control cells or SPHK1 siRNA-transfected cells. S1P enhanced endothelial barrier function in control cells (Figure 3F, right), whereas it restored barrier function in the SPHK1-deficient cells (Figure 3F, right).

We next addressed whether increasing SPHK1 activity would prevent thrombin-induced endothelial barrier dysfunction. Figure 3G shows SPHK activity and TER in HPAE cells infected with green fluorescent protein (GFP) (control) or SPHK1 adenovirus. Increasing SPHK1 activity by 5-fold attenuated the thrombin-induced decrease in TER and promoted endothelial barrier recovery, demonstrating the requirement of SPHK1 activation in not only maintaining normal endothelial barrier function but also promoting recovery of barrier function after endothelial junctional disruption induced by thrombin.
that S1P enhanced barrier (indicated by a sharp rise in TER) in cells transfected with scrambled siRNA. We observed that S1P had no effect on TER in cells transfected with S1P1 siRNA.

We next determined whether agonist activation of S1P1 could block the increase in vascular permeability induced by PAR-1 activation. WT lungs were perfused with S1P for 15 minutes, followed by 20 minutes of perfusion with PAR-1.
agonist peptide to activate SIP1 and PAR-1 sequentially, and lung vascular permeability was measured by determining the Kf,c. In WT lungs, pretreatment with S1P prevented the PAR-1–induced increase in lung microvascular permeability without affecting basal permeability (Figure 4D). In SphK1-null lungs, S1P reversed the increase in basal lung microvascular permeability (Figure 4E).

We also determined whether S1P administration could reverse the increased transvascular albumin permeability and lung edema formation following PAR-1 receptor activation in WT or Sphk1−/− mice. S1P or vehicle (control) was admin-

istered IV 15 minutes following IV administration of PAR-1 agonist peptide. With PAR-1 stimulation alone, Sphk1−/− lungs had greater transvascular albumin leakage and edema formation than WT lungs, consistent with the data shown in Figure 1F and 1G. As can be seen, S1P injection fully restored albumin leakage and edema formation induced by PAR-1 activation in both WT and Sphk1−/− lungs.

Discussion

Our findings have identified the indispensable role of endothelial SphK1 activity in mediating the reversal of increased
endothelial permeability. We showed that SPHK1 activation prevented the pulmonary edema elicited by 2 diverse inflammatory stimuli, thrombin and LPS, suggesting that SPHK1 serves a critical antiinflammatory function. The primary observation was that both thrombin and LPS activated SPHK1, leading to release of S1P from the endothelium, which by activating S1P1 receptor promoted reanastomosis of adherens junctions, thereby restoring endothelial permeability. The results support the concept the SIP acts locally in a paracrine manner. Thus, based on our data, we propose that SIP generated by upregulation of SPHK1 activity is a negative feedback mechanism that serves to limit the increase in endothelial permeability arising from diverse inflammatory stimuli.

We showed that endothelial cells and lung both expressed the 2 isoforms of SPHK, SPHK1 and SPHK2. Both enzymes generate S1P following activation; however, our data suggest that endothelial barrier function regulation is primarily the function of SPHK1. Lung tissue of Spkh1+/− mice had markedly reduced SPHK enzymatic activity compared to WT mouse lungs whereas the SIP concentration did not differ. Although the basis of normal lung SIP concentration in Spkh1+/− mice is not clear, studies have reported near normal SIP concentrations in other organs of SPHK1-null mice despite the low plasma S1P concentration. In lungs of Spkh1+/− mice, we found that SPHK2 did not compensate for the absence of SPHK1 because SPHK2 expression was similar to WT and SPHK activity of Spkh1+/− lungs was markedly reduced. Because sphingosine phosphatase or sphingosine phosphate lyase rapidly degrade S1P, a possible explanation for the normal lung tissue SIP concentration in Spkh1+/− mice may be compensatory reductions in enzymatic activities of sphingosine phosphatase or sphingosine phosphate lyase. The fact that SPHK2 did not compensate for the absence of SPHK1 and the endothelial permeability response was greatly enhanced in Spkh1+/− mice suggests that SPHK1 is the primary isozyme responsible for endothelial barrier regulation.

SPHK1 activity was markedly increased in WT mouse lungs following PAR-1 activation or LPS challenge, resulting in enhanced SIP generation and accompanied by reduced lung edema formation. SPHK1 activity was required for the restoration of lung vascular permeability after the vascular leak induced by either PAR-1 activation or LPS challenge because the permeability did not return to control values in the absence of SPHK1 expression. The lungs of these animals developed persistent edema. To address mechanisms of SPHK1-mediated endothelial barrier protection, we determined functional consequences of SPHK1 knockdown in endothelial monolayers. Knockdown of SPHK1 decreased both SPHK activity and intracellular SIP concentration by 80%. Also, SPHK1 deficiency markedly increased basal endothelial permeability to albumin and challenge of these cells with thrombin resulted in prolonged increase in permeability in contrast to full recovery seen within 2 hours in control endothelial cells. Thus, SPHK1 knockdown abrogated the recovery process and enhanced the permeability increase. Moreover, overexpression of SPHK1 counteracted PAR-1–induced barrier dysfunction. The knockdown of the SIP G protein–coupled receptor S1P1 in endothelial cells abolished the recovery process in response to thrombin challenge. We interpret these findings as suggesting that SPHK1-generated SIP from endothelial cells activates S1P1 receptor in a paracrine manner to restore barrier function. The mechanism of SIP release from endothelial cells remains an enigma. It is possible that ATP-binding cassette (ABC) transporters are involved because they are known to export SIP from cells.

We also showed that the basal lung vascular permeability of lungs from Spkh1−/− mice was considerably higher than WT mice. We did not observe gross alterations in lung morphology or differences in basal SIP concentrations that could account for the higher basal permeability in knockout mouse lungs. However, there was a strong correlation between constitutive SPHK1 activity and basal barrier function. Thus, a possible explanation may be that lower enzymatic activity and reduced release of SIP and S1P1 activation in the endothelium of Spkh1−/− lungs impaired endothelial barrier function. This scenario is likely because administration of SIP restored basal barrier function in Spkh1−/− lungs to near normal values.

RhoA and Rac1 have opposing effects in regulating endothelial barrier function. RhoA signals increased endothelial permeability and Rac1 reduces the response. We addressed the possibility that SPHK1 generation of SIP would either prevent RhoA activation or induce activation of Rac1. Inhibition of SPHK1 expression in endothelial cells augmented RhoA activity but also suppressed Rac1 activity in response to thrombin. Both of these changes in RhoA and Rac1 activities help to explain the persistent increase in endothelial permeability seen after SPHK1 knockdown. Moreover, overexpression of SPHK1 fully counteracted the thrombin-induced increase in endothelial permeability. The basis of the different effects of SPHK1-generated SIP on RhoA and Rac1 activities is not clear, but it likely involves SIP regulation of activities of GDI-1 (GDP dissociation inhibitor-1), GEFs (guanine nucleotide exchange factors), and GAPs (GTPase-activating proteins) in an orchestrated manner such that RhoA and Rac1 activities change in the opposing manner. Thus, a simple model to explain the effects of SPHK1-generated SIP may be that SIP acts as a rheostat that inactivates RhoA and activates Rac1, thereby restoring endothelial barrier.

Vascular injury is associated with activation of the coagulation cascade and release of thrombin, which increases endothelial permeability by activating endothelial cell surface PAR-1 signaling. Moreover, sepsis is known to upregulate the expression of PAR-1 receptor, suggesting a commonality between sepsis and PAR-1 activation. However, recent studies suggest that PAR-1 activation under specific conditions may signal endothelial barrier protection. Activated protein C, which reduces mortality of septic patients, was shown to convert PAR-1 signaling from being barrier-disruptive to barrier-protective. Pepducin, a cell-penetrating PAR-1–activating peptide, was protective during the later phase of sepsis, but its effect was mediated via upregulation and cross-activation of PAR-2. In the present study, we add to mechanisms by which PAR-1 activation may...
be protective. We describe a novel PAR-1–activated mechanism of endothelial barrier involving SPHK1 activation. This mechanism apparently does not require the upregulation of PAR-2 gene because SIP was sufficient to repair barrier after PAR-1 activation and in a time frame that precludes gene expression.

The signaling pathway between PAR-1 and the activation of SPHK1 is not known. Evidence shows that translocation of SPHK1 to the membrane is required to catalyze SIP formation from sphingosine.14,15 Extracellular signal-regulated kinase activation downstream of protein kinase C has been shown to phosphorylate SPHK1, leading to its activation.15,16 Binding with phosphatidyl serine and calmodulin also facilitates SPHK1 translocation.17–20 Because PAR-1 activates protein kinase C,1 SPHK1 activation may involve phosphorylation by protein kinase C pathway, which may translocate it to endothelial plasma membrane, resulting in SIP production and activation of SIP1 receptor and junctional reannealing. The present results have significant in vivo implications for diseases resulting from a pathological increase in vascular leakiness, such as acute lung injury, and may help in the development of novel therapeutics for specific activation of SPHK1 in endothelial cells.

Acknowledgments
We thank Drs Richard Proia (National Institute of Diabetes and Digestive and Kidney Diseases) for providing SPHK1-null mice and Maria Trojanowska (Medical University of South Carolina) for adenoviral-SPHK1 construct and Andrew Lee (Children’s Hospital Oakland Research Institute) for his technical support.

Sources of Funding
Supported by NIH grants RO1 CA77528 (to J.S.), HL45638 (to A.B.M.), and HL71794 and HL 84153 (to D.M.).

Disclosures
None.

References
Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability Through Sphingosine-1-Phosphate Receptor Signaling in Endothelial Cells
Mohammad Tauseef, Vidisha Kini, Nebojsa Knezevic, Melissa Brannan, Ram Ramchandaran, Henrik Fyrst, Julie Saba, Stephen M. Vogel, Asrar B. Malik and Dolly Mehta

Circ Res. 2008;103:1164-1172; originally published online October 10, 2008;
doi: 10.1161/01.RES.0000338501.84810.51
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/103/10/1164

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2008/10/10/01.RES.0000338501.84810.51.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Online data supplement

Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability through Sphingosine-1-Phosphate Receptor (SIP1) Signaling in Endothelial Cells

Mohammad Tauseef1*, Vidisha Kini1*, Nebojsa Knezevic1, Melissa Brannan1, Ram Ramchandaran1, Henrik Fyrst2, Julie Saba2, Stephen M. Vogel1, Asrar B. Malik1 and Dolly Mehta1

1Department of Pharmacology and Center for Lung and Vascular Biology, College of Medicine, University of Illinois, Chicago, Illinois; and 2Children’s Hospital Oakland Research Institute, Cancer Centre, Oakland, California

Running title: Sphingosine kinase-1 activation prevents vascular leak

*, equally contributed to the work


Key words: Sphingosine kinase, lung vascular permeability, thrombin, PAR-1, RhoGTPase, S1P1, S1P

Corresponding Author:
Dolly Mehta, Ph.D
Department of Pharmacology,
The University of Illinois,
College of Medicine,
835 S Wolcott Avenue,
Chicago, IL 60612.
Tel.: (312) 355-0236, Fax.: (312) 996-1225
E mail: dmehta@uic.edu
Expanded Methods

Animals: The generation and characteristics of the SPHK1-null mice are described elsewhere\(^1\). All animal studies were approved by the Institutional Animal Care and Use Committee of University of Illinois. \textit{Sphk1}\(^{-/-}\) male mice and corresponding wild type cohorts (8-10 wks old) used in all experiments were of C57Blk/6J background. All experiments involving animals were approved by the University of Illinois at Chicago Animal Care and Use Committee.

Endothelial cell culture: Human pulmonary arterial endothelial (HPAE) cells were cultured in a T-75 flask coated with 0.1% gelatin in EBM-2 medium supplemented with 10% fetal bovine serum and maintained at 37\(^{\circ}\)C in a humidified atmosphere of 5% CO\(_2\) and 95% air until they formed a confluent monolayer as described \(^2\).

Cell transfection: SPHK1 siRNA 5’ GAGCUGCAAGGCCCUGCC 3’ or control siRNA sequences were transduced into cells as described \(^2\). Briefly, HPAE cells grown to 70% confluence were trypsinized and mixed with 2.4 \(\mu\)g of siRNA along with 100 \(\mu\)l of HCAEC nucleofector solution. Cells were rapidly electroporated with an Amaxa nucleofector device in accordance with the manufacturer's recommended program (S-05), mixed in EBM-2 and plated on 60-mm dishes or coverslips for indicated experiments. HPAE cells plated onto gold electrodes, transwell or 12-mm coverslips were transfected with the indicated siRNA using SantaCruz transfection reagent in accordance with the manufacturer's protocol. The cells were used after 72 h of transfection, when there was clear evidence of the expression of protein.

RT-PCR: Total RNA was isolated from mouse lungs or HPAE cells using TRIzol\(^\text{\textregistered}\) reagent (Invitrogen Inc, Carlsbad, CA) according to the manufacturer’s instructions. RNA was quantified spectrophotometrically and reverse transcribed using primers to determine the expression of SPHK and S1P receptor. For analyzing the expression of SPHK isoforms in
mouse lung following mRNA primers sequences were used SPHK1 forward:
GGCAGTCATGTCCGGTGATG, reverse: ACAGCAGTGTGCAGTTGATGA and SPHK2
forward: ACAGAACCATGCCCCGTGAG, reverse: AGGTCAACACCGAACAACCTG.
Conditions for PCR reaction were: an initial 94°C denaturing for 1 min, followed by 31 cycles
of 94°C for 15s each, annealing at 53°C for 30s and termination at 72°C for 45s. The last cycle
was followed by a 5min reaction at 72°C. The PCR products were electrophoretically separated
on a 2% agarose gel. S1P receptor expression in mouse lungs was determined using following
primer sequences. S1P1 forward: GTCCGCATTACAACTACAC, reverse:
ATGAGGAGATGACCCAGCA; S1P2 forward: ACCGAGCAGCCCAAGTC, reverse:
GCCAGGTTGCCAAGGAACAG; S1P3 forward: GCTGGCCGCGATAGCATA, reverse:
GGATAAAAAGTGCTGGGACC; S1P4 forward: CCAATGGGCGAGTGCTCCA, reverse
CTAGGTGCTGCCAAGGACC; S1P5 forward: GGAGTAGGCTCCCCGAAGGACC, reverse,
TCTAGAATCCACGGGGTCTG. S1P receptor expression in HPAE cells was determined using
following primer sequences. S1P1 forward: GACTCTGCTGGCAAATTCAAGCGAC,
reverse: ACCCTTCCCAGTGCATTATGTGCT, reverse:
TCAGACCACCGTGTGGCCTC; S1P3 forward: CAAAATGAGGCCCTTACCGACGCA,
reverse: TCCCCATTCTGAAGTGCTGCTTCC; S1P4 forward: AGCCTCCTGCCCCTCTACTC,
reverse: GTAGATGATGGGTTGACCG; S1P5 forward: GGAGTAGGTCCCCGAAGGACC,
reverse: TCTAGAATCCACGGGGTCTG. PCR conditions were initial denaturation step at
94°C for 5 min, followed by 35 cycles consisting in 30 sec at 94°C, 45 sec at 52-62°C, 72°C for
1 min. After a final extension at 72°C for 10 min, PCR products were separated on 2% agarose
gel.
**Endothelial permeability:** Endothelial permeability was determined by determining the influx of Evans blue-labeled albumin across endothelial monolayer as described. Briefly, cells seeded on 0.4μ transwell filters (Corning Incorporated, NY) were transfected with indicated siRNA. Cells were then incubated in Hanks’ balanced salt solution (GIBCO-BRL) containing 0.5% bovine serum albumin (BSA) and 20 mM HEPES buffer on both sides of the monolayer. The luminal compartment buffer was labeled with a final concentration of 0.057% Evans blue dye in a volume of 700 µl. The absorbance of free Evans blue in the luminal and abluminal compartments was always <1% of the total absorbance of Evans blue in the buffer. At the beginning of each measurement a luminal compartment sample was diluted 1:100 to determine the initial absorbance of that compartment. Abluminal compartment samples (100 µl) were taken every 5 min for up to a period of 60 min. The absorbance of the samples was measured in a SpectraMax Plus microplate spectrophotometer (Molecular Devices, Sunnyvale, CA) at 620 nm. The clearance rate of Evans blue-labeled albumin was determined by least-squares linear regression between 5 and 60 min for the control and experimental groups.

We also determined endothelial permeability by determining transendothelial electrical resistance (TER) in real time as described.

**Confocal staining:** Cells stimulated with thrombin for indicated times were fixed and incubated with indicated antibody and counter stained with Alexa-Donkey anti Goat 488. Cells were viewed with a 63× 1.2 NA objective and a Zeiss LSM 510 confocal microscope.

**Sphingosine Kinase Activity:** HPAE cells or mouse lungs were homogenized in buffer (containing in mM, 20 Tris (pH 7.4), 20% glycerol, 1 mercaptoethanol, 1 EDTA, 1 sodium orthovanadate, 40 β-glycerophosphate, 15 NaF, 1 phenylmethylsulfonyl fluoride, 0.5 4-deoxypyridoxine and 10 µg/ml each of leupeptin, aprotinin, and soybean trypsin inhibitor).
Lysates containing 40 µg of protein were then mixed in a total volume of 190 µl homogenizing buffer plus 10 µl of 1 mmol/l sphingosine and 10 µl of [32P]ATP (10 µCi, 20 mmol/l) and incubated for 30 min at 37 °C. Reactions were terminated by addition of 20 µl of 1 N HCl followed by 0.8 ml of chloroform/methanol/HCl (100:200:1, v/v). After vigorous vortexing, 240 µl of chloroform and 240 µl of 2 M KCl were added, organic phases were separated by centrifugation and lipids were resolved by thin layer chromatography in solvent system containing 1-butanol/ethanol/acetic acid/water (80:20:10:20, v/v) and visualized by autoradiography. The radioactive spots corresponding to authentic S1P were identified, scraped from the plates, and counted in a scintillation counter. Sphingosine kinase specific activity was calculated and expressed as pmol of S1P formed per min (unit)/mg of protein.

**S1P Measurements:** HPAE cells were spun down and 200 pmol of C17-S1P as internal standard was added. Cell pellet was dissolved in water and cells were lysed by tip sonicator. A two phase system was obtained by adding CHCl3/MeOH/NH4OH. The aqueous phase was recovered and acidified by adding 0.5 ml glacial acetic acid. Another two phase separation was obtained by adding one volume of chloroform. Organic phase was recovered and dried down with a flow of nitrogen. Samples were resuspended in methanol and analyzed using LC-mass spectroscopy as described. Lung S1P was extracted as above except that 2 nmol of internal standard C17-S1P was added to homogenates.

**Measurement of GTPase activity:** RhoA and Rac1 activities were measured using GST-rotekin-RBD binding and GST-PAK binding beads respectively as described.

**LPS treatment:** Wild type and Sphk1−/− mice were exposed to LPS as described previously. Briefly, mice housed in sealed container were exposed to a nebulized solution of lyophilized E. coli LPS in sterile saline (1 mg/ml) for 45 min at a driving flow rate (8 l/min) using a small
volume nebulizer (Resigard II; Marquest Medical, Englewood, CO) and sacrificed after indicated time.

**Assessment of Lung Capillary Leakage:** Evans blue dye albumin (EBA) (20 mg/kg) was injected retro-orbitally 30 minutes before the termination of the experiment to assess vascular leak as described \(^9\). The lungs were perfused free of blood (perfusion pressure of 5 mm Hg) with phosphate-buffered saline (PBS) containing 5 mM ethylenediaminetetraacetic acid via thoracotomy, excised *en bloc*, blotted dry, weighed, and snap frozen in liquid nitrogen. The right lung was homogenized in PBS (1 ml/100 µg tissue), incubated with 2 volumes of formamide (18 hours, 60°C), and centrifuged at 5,000 x g for 30 minutes, and the optical density of the supernatant was determined spectrophotometrically at 620 nm. The extravasated EBA concentration in lung homogenate was calculated against a standard curve (micrograms Evans blue dye per lung).

**Pulmonary microvascular permeability:** *Sphk1*−/− and WT mice were anesthetized with an *i.p.* injection of ketamine (100 mg/kg) and xylazine (2.5 g/kg). We measured microvessel permeability in the lung by determining microvascular filtration coefficient (K<sub>f,c</sub>) and isogravimetric lung water determinations as described \(^6,10\). Briefly, after establishing isogravimetric lungs, outflow pressure was elevated by 10 cm H<sub>2</sub>O for 20 min. The lung wet weight increase over this time, which reflects the net fluid accumulation, was continuously recorded. At the end of each experiment, lung dry weight was determined. K<sub>f,c</sub> (ml·min<sup>-1</sup>·cm H<sub>2</sub>O·g dry wt<sup>-1</sup>) was calculated from the slope of the recorded weight change normalized to the pressure change and lung dry weight.

**Drug infusion:** In the isolated murine lung preparations, drugs were infused through a side-port in the perfusion cannula at a rate of 0.2 ml/min such that the total flow through the lung
vasculature remained at 2 ml/min. S1P (final concentration, 1 μmol/l) was infused 15 min before perfusing PAR-1 agonist peptide (TFLLRN-NH₂; perfusate concentration, 10 μmol/l). PAR-1 agonist peptide or control peptide (FTLLRN-NH₂; 1 mg/kg) and S1P (final concentration 1 μmol/l) were administered through retroorbital route.

**Lung weight determination:** Left lungs from the same mouse, which we used for Evans blue albumin extravasation, were excised and completely dried in the oven at 60°C overnight for calculation of lung wet-dry- ratio.\(^{11}\)

**Lung histology:** Formalin fixed tissues were dehydrated in 70% ethanol and four-micrometer-thick sections were stained with hematoxylin-eosin and examined by light microscopy. Infiltration of neutrophils was quantified by determining the number of neutrophils adhered/ mm\(^2\) lung surface area.

**Statistical analysis:** One way ANOVA and post-hoc \(t\)-test was used to compare data between groups. \(p < 0.05\) was considered statistically significant.
References


Online Figure Legend

Online Figure 1: Expression of S1P receptor isoforms in mouse lungs and human endothelial cells.

RT-PCR of S1P receptor expression in WT mouse lungs (A) and HPAE cells (B). RNA extracted from lungs or cells was treated with DNAase and reverse-transcribed using suitable primers as described in Methods. GAPDH was used as internal control.
Online Figure I

A

B

S1P1  S1P2  S1P3  S1P4  S1P5  GAPDH

S1P1  S1P2  S1P3  S1P4  S1P5  GAPDH